#USA #San Diego #Class Action #Securities Fraud #Regeneron

Regeneron Pharmaceuticals Class Action Lawsuit: A Call to Investors

Introduction

Amid significant losses reported by shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), an opportunity has arisen for impacted investors to lead a class action lawsuit. Robbins Geller Rudman & Dowd LLP, a prominent law firm, announced that those who purchased Regeneron securities between November 2, 2023, and October 30, 2024, can seek appointment as lead plaintiff by March 10, 2025.

Background on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is a biotechnology firm known for developing innovative treatments for eye diseases, as well as allergic and inflammatory conditions, various cancers, and cardiovascular issues. One of their flagship products, Eylea, is utilized for treating age-related macular degeneration and other ailments. Recent allegations suggest that the company may have engaged in misleading practices, impacting their stock value and investor trust.

Allegations Against Regeneron

The class action lawsuit, titled Radtke v. Regeneron Pharmaceuticals, Inc., accuses the company of violating the Securities Exchange Act of 1934. The allegations focus on misleading statements made by company executives and undisclosed financial practices that manipulated Eylea's pricing structure and sales reports, which ultimately misled investors.

Key Allegations Include:

1. Unreported Credit Card Fees: It is claimed that Regeneron paid credit card fees to sellers, effectively lowering the out-of-pocket costs for customers using credit cards. This practice purportedly distorted the reported selling price of Eylea and created a deceptive sales advantage over competitors.
2. Inflated Average Sales Price: By failing to disclose these fee payments, Regeneron reportedly overstated the Average Sales Price (ASP) of Eylea, leading to fraudulent claims to federal agencies.
3. Federal Investigation: Following these allegations, the U.S. Department of Justice charged Regeneron under the False Claims Act, indicating that the price adjustments in question led to inflated Medicare reimbursements.
4. Stock Price Decline: The announcement of these legal challenges and subsequent financial disclosures reportedly triggered a notable decline in Regeneron's stock price.

The Path to Becoming a Lead Plaintiff

The Private Securities Litigation Reform Act of 1995 allows investors with the greatest financial stake to take the lead in this type of lawsuit, representing all affected parties. Interested investors must demonstrate their financial interest and suitability for the role of lead plaintiff. Selecting a legal team, like Robbins Geller, can significantly influence the proceedings of the class action.

Call to Action

Investors who have incurred substantial losses due to Regeneron's alleged actions should take immediate steps to assert their rights. By visiting Robbins Geller’s website or reaching out directly to their attorneys, affected investors can explore their options to represent the class in court.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP stands as a leading force in securities fraud litigation, renowned for its track record in recovering financial losses for investors. Having secured over $6.6 billion in securities-related recoveries, the firm's expertise can prove invaluable for those seeking justice in the Regeneron case.

Conclusion

As the deadline for seeking lead plaintiff status approaches, it is crucial for Regeneron investors facing losses to consider their options carefully. This class action lawsuit presents a chance not only to potentially recover losses but also to hold the company accountable for its actions. For more information, reach out to Robbins Geller or review their official communications for further guidance.